Company Overview and News

 
Willowglen rises 6.20% on securing RM139.36m Gemas-JB job

2018-10-08 theedgemarkets
KUALA LUMPUR (Oct 8): Willowglen MSC Bhd rose 6.20% early today after it secured a RM139.36 million contract from Syarikat Pembenaan Yeoh Tiong Lay Sdn Bhd to construct and maintain communication systems for the Gemas-Johor Bahru electrified double-track project.
0008

 
Willowglen shares gain 7% on contract win

2018-10-08 thestar.com.my
KUALA LUMPUR: Shares of Willowglen MSC Bhd gained 7% in early trade Monday after the company secured a RM139.36mil contract.
0008

 
Trading ideas: Willowglen, Zelan, MMHE, EA Technique, MMC-Gamuda

2018-10-08 thestar.com.my
KUALA LUMPUR: Willowglen MSC Bhd , Zelan Bhd , Malaysia Marine Heavy Engineering Holdings Bhd, EA Technique (M) Bhd and MMC-Gamuda are among the stocks to watch today, according to JF Apex Research.
0008 DONGY

 
KLCI seen trading range bound, hurdle at 1,790

2018-10-07 theedgemarkets
KUALA LUMPUR (Oct 8): Sentiment at the local market is seen dampened today, tracking the slump at most global markets last Friday, and the FBM KLCI is expected to trade range bound with hurdle at 1,790 points.
0049 0008 8664 7374

 
Inta Bina, Oceancash, EA Technique, MHB, MyEG, S P Setia, SimeProp, Tien Wah, Willowglen and Zelan

2018-10-05 theedgemarkets
KUALA LUMPUR (Oct 5): Based on corporate announcements and news flow today, companies that may be in focus on Monday (Oct 8) may include the following: Inta Bina Group Bhd, Oceancash Pacific Bhd, EA Technique Bhd, Malaysia Marine Heavy Engineering Holdings Bhd, My EG Services Bhd, S P Setia Bhd, Sime Darby Property Bhd, Tien Wah Press Holdings Bhd, Willowglen MSC Bhd and Zelan Bhd.
0049 0008 8664 DONGY BSMAF 7374 1818

 
Willowglen bags RM139.36mil rail job

2018-10-05 thestar.com.my
KUALA LUMPUR: Willowglen MSC Bhd has secured a RM139.36mil contract for the design, construction and commissioning of communication systems for the Gemas-Johor Baru electrified double track railway project.
0008

 
Willowglen bags RM139.36m contract for Gemas-JB electrified railway project

2018-10-05 theedgemarkets
KUALA LUMPUR (Oct 5): Computer integrated systems design company Willowglen MSC Bhd today secured a RM139.36 million contract in relation to the Gemas-Johor Bahru electrified double-track project.
CWYCF CWYCY 0008 BSMAF 1818

 
Trading ideas: SCGM, Willowglen, Icon Offshore, GPacket

2018-06-25 thestar.com.my
KUALA LUMPUR: SCGM Bhd , Willowglen MSC Bhd , Icon Offshore Bhd and Green Packet Bhd are among the stocks to watch, according to JF Apex Research.
0008 0082 5255

2
Willowglen, Icon, Green Packet, Comfort Gloves, Kimlun, MAHB, Fitters, SCGM

2018-06-22 theedgemarkets
KUALA LUMPUR (June 22): Based on corporate announcements and news flow today, companies that may be in focus on Monday (June 25) may include the following: Willowglen MSC Bhd, Icon Offshore Bhd, Green Packet Bhd, Comfort Gloves Bhd, Kimlun Corp Bhd, Malaysia Airports Holdings Bhd (MAHB), Fitters Diversified Bhd and SCGM Bhd.
9318 2127 0008 MYPRY 0082 5014 5255

 
Willowglen bags RM8.62m maintenance contract

2018-06-22 theedgemarkets
KUALA LUMPUR (June 22): Willowglen MSC Bhd's subsidiary Willowglen Services Pte Ltd has bagged a RM8.62 million contract to undertake maintenance of 30 document management solutions (DMS) product data management (PDM) systems and the upgrade of 22 PDM system workstations.
0008 5053

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...